Pimavanserin Added to Treatment for Schizophrenia: A Placebo-Controlled Trial
About this title
Read the official source — NCT02970292This study evaluated the safety and effectiveness of Pimavanserin for people with schizophrenia.
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Pimavanserin for people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
- Listed locations
- Phoenix and 104 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 396
- Sponsor
- ACADIA Pharmaceuticals Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Canada, Bulgaria, ...
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT02970292
- Official title
Show the full official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Phoenix, United States · Little Rock, United States · Rogers, United States
81 more locations
- Bellflower, United States
- Cerritos, United States
- Culver City, United States
- Lemon Grove, United States
- Long Beach, United States
- San Diego, United States
- Santa Ana, United States
- Torrance, United States
- Boca Raton, United States
- Lauderhill, United States
- Miami, United States
- Atlanta, United States
- Chicago, United States
- Hoffman Estates, United States
- Lake Charles, United States
- Catonsville, United States
- Ann Arbor, United States
- Las Vegas, United States
- Berlin, United States
- Cedarhurst, United States
- Jamaica, United States
- Rochester, United States
- Charlotte, United States
- Dayton, United States
- Charleston, United States
- Richardson, United States
- Salt Lake City, United States
- Burgas, Bulgaria
- Pazardzhik, Bulgaria
- Plovdiv, Bulgaria
- Sofia, Bulgaria
- Targovishte, Bulgaria
- Tserova Koria, Bulgaria
- Varna, Bulgaria
- Veliko Tarnovo, Bulgaria
- Vratsa, Bulgaria
- Chatham, Canada
- Montreal, Canada
- Toronto, Canada
- Hradec Králové, Czechia
- Pilsen, Czechia
- Prague, Czechia
- Říčany, Czechia
- Kalocsa, Hungary
- Budapest, Hungary
- Debrecen, Hungary
- Pécs, Hungary
- Kaunas, Lithuania
- Šilutė, Lithuania
- Vilnius, Lithuania
- Bialystok, Poland
- Bydgoszcz, Poland
- Lublin, Poland
- Pruszcz Gdański, Poland
- Roshchino, Russia
- Plekhanovo, Russia
- Tonnel’nyy, Russia
- Arkhangelsk, Russia
- Moscow, Russia
- Saint Petersburg, Russia
- Samara, Russia
- Smolensk, Russia
- Stavropol, Russia
- Voronezh, Russia
- Yaroslavl, Russia
- Belgrade, Serbia
- Kovin, Serbia
- Kragujevac, Serbia
- Niš, Serbia
- Kherson, Ukraine
- Dnipro, Ukraine
- Hlevakha, Ukraine
- Kharkiv, Ukraine
- Kyiv, Ukraine
- Odesa, Ukraine
- Oleksandrivka, Ukraine
- Poltava, Ukraine
- Smila, Ukraine
- Vinnytsia, Ukraine
- Czechia
- Russia
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Pimavanserin for people with schizophrenia.
Who is behind this study?
The study sponsor is ACADIA Pharmaceuticals Inc.
Did this study involve medication?
Yes. The study involved medication, including Pimavanserin and Placebo.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
